Tag Archives: medical treatment

Beta Bloqueantes

Post MI Betablockers for Good?

Post MI Betablockers for Good?

Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.  This study looked into the cardio protection effect of betablockers (BB) after long term follow up in stable patients with no cardiac failure and a history

Saltearse el desayuno y riesgo cardiovascular

Regression of High-Risk Plaque with Lifestyle Changes

Diet and lifestyle intervention in addition to optimal medical therapy can slow down plaque building and even reduce plaque volume compared against optimal medical treatment (OTM) alone. Diet and lifestyle intervention are amongst the most important strategies to manage coronary artery disease. However, its direct impact on atherosclerosis remains unclear.  Atherosclerosis plaque building is associated

Subutilización del tratamiento médico en enfermedad vascular periférica

Optimal Medical Treatment Under-used in Vascular Peripheral Disease

Less than half of patients undergoing endovascular revascularization for peripheral artery disease to their lower limbs are discharged with optimal medical treatment.  Their traditional risk factors are predictors of a more comprehensive treatment; however, women, patients with higher risk of thrombosis, and those more likely to lose a lower limb, are far from being treated

Tratamiento médico óptimo

Is Medical Treatment Better at Lowering Bleeding-Caused Mortality than Angioplasty?

Post-discharge bleeding in patients admitted for acute coronary syndrome (ACS) is linked to higher all-cause mortality. However, this is the case for both patients who underwent angioplasty and those who were managed with medical treatment. These are interesting data, given that medical treatment is frequently preferred due to lower bleeding risk. Speculation is based on

Seguridad de los balones con paclitaxel en enfermedad vascular periférica

Peripheral Artery Disease: Underestimated and Undertreated

Compared against coronary artery disease (CAD) or cerebrovascular disease patients, peripheral artery disease (PAD) patients have lower chances of receiving medication proved to be clinically effective such as statins (despite running the same risk, perhaps even higher risk).  The message is we should be more active both in finding risk factors in PAD patients, and

Revascularización vs tratamiento médico inicial en pacientes crónicos

EuroPCR 2020 | Revascularization vs. Initial Medical Treatment in Chronic Patients

There is no survival advantage with invasive coronary revascularization over initial medical treatment in patients with chronic coronary artery disease.  However, revascularization did reduce the incidence of unstable angina and its symptoms, according to this new meta-analysis published in Circulation and presented virtually at EuroPCR 2020. There was no significant difference in spontaneous infarctions overall, but

AHA 2019 | ISCHEMIA-CKD: insuficiencia renal crónica y enfermedad coronaria estable

AHA 2019 | ISCHEMIA-CKD: Chronic Kidney Disease and Stable Coronary Disease

Among patients in the main ISCHEMIA trial, those with chronic kidney disease are a particularly high-risk subgroup. However, an invasive strategy with coronary angiography and revascularization did not improve the rate of events, similarly to what happened in the general population for the aforementioned trial. The rate of death or acute myocardial infarction was 36.4%

Infarto agudo de miocardio y lesiones de múltiples niveles

STEMI in Coronary Dissections. When Should We Do It and What Are Its Outcomes?

Courtesy of Dr. Carlos Fava. Generally, coronary artery dissection (SCAD) is not very frequent in young women and presents better evolution with medical treatment. However, it is occasionally associated with ST segment elevation. In this scenario, PCI with stent implantation is quite challenging. The study looked at 4298 STEMI patients; 53 presented SCAD (1.23%). STEMI-SCAD

Antianginal Medication Before and After Rechanneling

Escalation or de-escalation of antianginal medication was less common than treatment continuation without change after a chronic total occlusion rechanneling, with little variation according to the site. Further research is needed to identify patients who would benefit (or not) from these drugs and to develop strategies to adjust treatment during follow-up. This work basically tells

TAVI en insuficiencia aórtica pura, nuevos dispositivos con nuevos resultados

The FDA Affirms Mortality Signs with Paclitaxel Based Devices

Evidently, we are still uncertain. The information goes both ways, even on our own web page, we have been coming and going just like any other publication around the world. After a 2-day debate, the Circulatory System Devices FDA panel has confirmed the tendency to higher mortality with paclitaxel-based devices and is expected to debate